Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Context: The lack of knowledge of the accurate conversion ratio (CR) between intravenous (IV) and oral hydromorphone and opioid rotation ratio (ORR) between IV hydromorphone and oral morphine equivalent daily dose (MEDD) may lead to poorly controlled pain or overdosing in cancer inpatients.
Objectives: We aimed to determine the CR and ORR from IV hydromorphone to oral hydromorphone and MEDD (obtained from oral morphine and oxycodone).
Methods: A total of 4745 consecutive inpatient palliative care consults during 2010-14 were reviewed for conversions from IV hydromorphone to oral hydromorphone, morphine or oxycodone. Patient characteristics, symptoms, and opioid doses were determined in patients successfully discharged on oral opioids without readmission within one week. Linear regression analysis was used to estimate the CR or ORR between the 24 hour IV hydromorphone mg dose before conversion and the oral opioid mg dose used before discharge.
Results: Among 394 patients on IV hydromorphone, 147 underwent conversion to oral hydromorphone and 247 underwent rotation to oral morphine (163) or oxycodone (84). The median (interquartile range) CR from IV to PO hydromorphone was 2.5 (2.14-2.75) with correlation of 0.95 (P < 0.0001). The median ORR (interquartile range) from IV hydromorphone to MEDD was 11.46 (9.84-13.00) with correlation of 0.93(P < 0.0001). The median ORR was 11.54 in patients receiving <30 mg of IV hydromorphone/day and 9.86 in patients receiving ≥30 mg (P = 0.0004).
Conclusion: Our study found that 1 mg of IV hydromorphone is equivalent to 2.5 mg of oral hydromorphone and 11.46 mg of MEDD. Hydromorphone at doses ≥30 mg/day may require a lower ORR to other opioids.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jpainsymman.2017.07.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
UGT2B7-mediated drug-drug interaction between cannabinoids and hydromorphone.
Drug Metab Dispos
July 2025
Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington; Division of Molecular Biosciences, Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York
Hydromorphone is a highly potent opioid used to treat severe chronic pain. It is metabolized primarily by UDP-glucuronosyltransferase (UGT)2B7 to form the inactive hydromorphone-3-glucuronide. Given that previous studies have shown that the major cannabinoids, Δ-tetrahydrocannabinol (THC) and cannabidiol (CBD), inhibit several UGT enzymes, the objective of the present study was to determine the inhibitory potential of major cannabinoids and their metabolites on UGT-mediated hydromorphone metabolism.
View Article and Find Full Text PDFInadequate Cancer Pain Control after Switching High-Dose Fentanyl to Hydromorphone Injection: A Case Series Highlighting Issues with Conventional Conversion Ratios.
Palliat Med Rep
September 2025
Department of Pharmacy, Yamagata Prefectural Central Hospital, Yamagata, Yamagata, Japan.
Opioid conversion, particularly from high-dose intravenous (IV) fentanyl (>120 mg/day oral morphine-equivalent daily dose per referenced Japanese guidelines) to IV hydromorphone, presents clinical challenges due to inconsistent conversion ratios and lack of robust evidence. Specific approaches used in Japan may require careful evaluation. This report details two advanced cancer patients experiencing inadequate pain control after switching from high-dose IV fentanyl to IV hydromorphone.
View Article and Find Full Text PDFOral and injectable opioid agonist treatments for people who use street opioids: a systematic literature review and network meta-analysis.
BMC Public Health
August 2025
School of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Objective: To synthesize and determine the relative effectiveness of diverse opioid agonist treatment (OAT) medications, including injectables, for opioid use disorder (OUD).
Methods: We searched EMBASE, PubMed, and CENTRAL for Randomised Controlled Trials (RCTs) (CRD42018109469) and previously published systematic reviews of head-to-head trials of OAT medications. The primary outcome was treatment retention, and secondary outcomes included days of opioid use, days of cocaine use, and proportion of participants involved in criminalized activities.
Implementation of an opioid-sparing protocol utilizing liposomal bupivacaine and intravenous ketorolac for pain management after living kidney donation.
World J Transplant
September 2025
Department of Pharmacy, Temple University Hospital, Philadelphia, PA 19140, United States.
Background: Opioids are commonly used for management of post-operative pain in living kidney donors. Reducing exposure to opioids is desirable to minimize risk of dependence and potential side effects such as nausea, vomiting, and constipation which may delay discharge. Liposomal bupivacaine, ketorolac, and scheduled acetaminophen have all demonstrated efficacy for management of post-operative pain in this population.
View Article and Find Full Text PDFComparison of different hydromorphone bolus doses in patient-controlled intravenous analgesia for post-laparoscopic surgery: a randomized controlled trial.
BMC Anesthesiol
August 2025
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, No. 3 Qingchun East Road, Shangcheng District, Hangzhou, Zhejiang Province, China.
Purpose: This study aimed to evaluate the analgesic efficacy and safety profile of varying bolus doses of hydromorphone administered via patient-controlled intravenous analgesia (PCIA) in patients undergoing laparoscopic surgery.
Patients And Methods: In this randomized controlled trial, 111 patients undergoing laparoscopic surgery were randomly allocated into three groups, each receiving hydromorphone PCIA without background infusion. The groups differed by bolus dose: Group A (0.